Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers.
Conclusions: The intra- and perilesional application of rhEGF is a more effective therapeutic option than conventional therapy in the treatment of patients with Wagner's 3 or 4 diabetic foot ulcers and is cost-effective, taking as an outcome the QALYs for Colombia from the perspective of the health system.
PMID: 29963295 [PubMed]
Source: Diabetic Foot and Ankle - Category: Endocrinology Tags: Diabet Foot Ankle Source Type: research
More News: Colombia Health | Diabetes | Diabetic Ulcers | Disability | Endocrinology | Health Management